Here’s everything you need to know to about how to integrate apps into your clinical practice.
There has been much thought and discussion about the relationship between pediatrics and psychiatry, but research on the integration of the two leaves much to the imagination.
Available data suggest that transcranial magnetic stimulation holds promise as a treatment for GAD. Here: a look at what we know.
Dr Thompson introduces a Special Report meant to provoke thoughtful contemplation on various topics related to aggressive behavior.
A review of the pharmacological and symptomatic effects of various classes of designer drugs, including stimulants, hallucinogens, and sedatives.
For pharmaceutical companies, off-label use of a drug represents a substantial “gray market,” to which the company is unable to sell their product directly, yet may be a significant revenue stream. Some drugs have been used more for off-label purposes than for originally approved indications.1
While patients with restless legs syndrome may be successfully treated with a number of medications, comorbid psychiatric conditions present a unique challenge because many commonly prescribed psychiatric medications may worsen RLS symptoms.
Writers of diagnostic criteria should consider their work and all its implications. What about adding a new disorder? What might that do to epidemiological capture? Depending on the characteristics of the diagnostic criteria set, many possibilities exist.
Autism spectrum disorders (ASDs) are a group of 5 neuro developmental conditions (autism, Asperger syndrome, pervasive developmental disorder not otherwise specified [PDD-NOS], Rett syndrome, and disintegrative childhood disorder).1 Once thought to be rare, the incidence of these disorders is now estimated to be 1 in 150 children in the general population.2 Furthermore, the number of recognized cases has increased markedly in recent years.
As the United States becomes more culturally, racially, and ethnically diverse, psychiatry will be faced with the need to treat more diverse populations. This article focuses on challenges and obstacles encountered when treating black patients with mental illness.
Because at least 10% of the US population suffers from a substance use disorder in any given year, the American Academy of Addiction Psychiatry has expanded its longstanding Board Review Course in Addictions to a more inclusive “Addictions and Their Treatment” course.
Because patients who have psychiatric illnesses typically receive less frequent medical care, psychiatrists must aim to ensure appropriate monitoring of metabolic parameters when antipsychotic medications are used.
No other psychiatric diagnosis has more profound negative implications than autism. On the surface, autism impacts social, emotional, behavioral, and academic functioning. However, autism is pervasive in ways less immediately observable, and, as a result, children with autism require developmental and educational interventions that are different in both form and intensity from those required by children with other special needs.
Bipolar disorder frequently co-occurs with OCD and complicates treatment of OCD symptoms. Special considerations are discussed.
Cultural psychiatry can no longer be thought to involve only unusual syndromes that occur in distant societies. The growing literature in attests to the vitality of this field.
Evidence-Based Therapies in Child and Adolescent Psychiatry by Jon McClellan, M.D. Given the lack of large, randomized controlled studies of psychiatric medications that involve children and adolescents, it can be difficult to establish evidence-based therapies that are effective for this population. However, there are studies that have shown the effectiveness of various medications, as well as for various psychotherapy techniques.
A considerable overlap exists between TBI and disorders in cognition, behavior, and personality, which can provide even greater clinical challenges. More than 70% of the cases of TBI are mild, which makes this subgroup of particular clinical interest.
"There must be some way out of here," said the joker to the thief."There's too much confusion, I can't get no relief. . . .""No reason to get excited," the thief, he kindly spoke,"There are many here among us who feel that life is but a joke.But you and I, we've been through that, and this is not our fate,So let us not talk falsely now, the hour is getting late."From "All Along the Watchtower," Bob Dylan
The goal of treating the whole patient, ie, integrating the mind-body connection into mental health care inititiatives, is to provide health care professionals with tactics to effectively identify interdependent conditions of the mind and body that impair psychiatric well-being, as well as strategies for successful treatment and management options in the clinical setting to improve patient care, outcomes, and overall wellness.
How can novel technologies help address stigma and improve care for patients with SUDs?
Although the onset of psychotic symptoms before the age of 13 years is exceedingly rare, the incidence of schizophrenia rises sharply after the onset of puberty.1 Only 1% of the population has schizophrenia and 30% of these patients experience an onset of psychotic symptoms by age 18 years.2-8 The period that precedes the onset of frank psychotic symptoms (ie, the prodromal phase) has not been well characterized in early-onset schizophrenia-spectrum disorders (EOSS), but retrospective reports have shown that symptoms include high levels of depression and anxiety, emerging cognitive and social deficits, unusual thought content, and (not infrequently) school failure.
Mental health professionals, state-run forensic services, and law enforcement agencies need to come together and discuss the most efficient and safe models when confronting psychiatric emergencies to improve and expand these practices across America.
Clinicians can feel confident in the evidence base when referring patients with a moderate level of treatment resistance for rTMS. Preliminary results suggest that deep rTMS may be an effective option in patients who have failed to respond to more than one antidepressant treatment.
The potential of TMS as a treatment for cognitive disorders, fatigue, pain, and other manifestations of brain disease is discussed, as is the encouraging prospect for neuropsychiatric management of many patients.
The prescription of psychotropic medications for children continues to be a controversial area of medical practice. In the United States, academic medical centers, medical researchers, prescribers, and the FDA are all ostensibly committed to the common goal of disseminating accurate information and promoting treatment based on scientific evidence. In the United States, however, medical treatment takes place in the context of legal and pervasive direct-to-consumer advertising (DTCA). There are concerns about the potential for DTCA to affect public health negatively and to increase health care costs.
This review critically addresses 4 central assumptions that underlie many US political and popular associations between gun violence and mental illness.
Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.
This Special Report addresses several specific areas of concern that are of importance to psychiatrists: Can depression be prevented after traumatic brain injury? What are the risks? Are there special issues involved in treatment?
Recent research has shown environmental factors may increase the risk of schizophrenia in persons who may already have a genetic predisposition toward the illness.